NCT06132828View on ClinicalTrials.gov

Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

216

Participants

Timeline

Start Date

November 27, 2023

Primary Completion Date

March 30, 2026

Study Completion Date

July 30, 2026

Conditions

Solid Tumor

Interventions

DRUG

DR30206

Subjects receive DR30206 intravenously

Trial Locations (1)

200433

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors

lead

Zhejiang Doer Biologics Co., Ltd.

INDUSTRY